<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03665753</url>
  </required_header>
  <id_info>
    <org_study_id>9521307004</org_study_id>
    <nct_id>NCT03665753</nct_id>
  </id_info>
  <brief_title>Comparison of IV 10, 20, and 30mg for Renal Colic Pain in the ED</brief_title>
  <official_title>Comparison of Intravenous Ketorolac 10, 20, and 30mg for Treating Renal Colic Pain in the Emergency Department: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Intravenous administration of Ketorolac 10 mg and 20 mg is as effective as 30 mg
      in treating renal colic pain in patients presenting to the emergency department
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that is widely used in the
      Emergency Department (ED). Because of the Ketorolac significant analgesic potency, it is
      usually used for moderate-to-severe pain. However, ketorolac has several side effects, of
      which gastrointestinal hemorrhage is most concerning. &quot;Analgesic ceiling&quot; is defined as the
      dose beyond which no additional analgesia can be achieved and on the other hand, more side
      effects might be encountered. Several studies suggested 10 mg as analgesic ceiling. Despite
      this, many recommendations are still advocating several folds higher doses (e.g. 30, 60 mg).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2018</start_date>
  <completion_date type="Actual">November 9, 2019</completion_date>
  <primary_completion_date type="Actual">September 9, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain assessed with visual analogue scale (VAS)</measure>
    <time_frame>30 Minutes</time_frame>
    <description>The visual analogue scale (VAS) will be used for the study. The VAS ranges from 0 (no pain) to 100 (very severe pain). The higher the pain scores the higher the pain severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain assessed with visual analogue scale (VAS)</measure>
    <time_frame>15 Minutes</time_frame>
    <description>The visual analogue scale (VAS) will be used for the study. The VAS ranges from 0 (no pain) to 100 (very severe pain). The higher the pain scores the higher the pain severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessed with visual analogue scale (VAS)</measure>
    <time_frame>45 Minutes</time_frame>
    <description>The visual analogue scale (VAS) will be used for the study. The VAS ranges from 0 (no pain) to 100 (very severe pain). The higher the pain scores the higher the pain severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessed with visual analogue scale (VAS)</measure>
    <time_frame>60 Minutes</time_frame>
    <description>The visual analogue scale (VAS) will be used for the study. The VAS ranges from 0 (no pain) to 100 (very severe pain). The higher the pain scores the higher the pain severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>60 Minutes</time_frame>
    <description>Dizziness (Adverse Effect), Nausea (Adverse Effect), Vomiting (Adverse Effect), headache (Adverse Effect)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Pain</condition>
  <condition>Renal Colic</condition>
  <arm_group>
    <arm_group_label>Ketorolac 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered 10 mg of Ketorolac.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered 20 mg of Ketorolac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As a part of standard care, subjects will be administered 30 mg of Ketorolac.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Subject will receive 10, 20, and 30mg of Ketorolac.</description>
    <arm_group_label>Ketorolac 10mg</arm_group_label>
    <arm_group_label>Ketorolac 20mg</arm_group_label>
    <arm_group_label>Ketorolac 30mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe flank and abdominal pain which pertains to renal colic according to emergency
             physician's gestalt

        Exclusion Criteria:

          -  Age &gt;65

          -  Active Peptic Ulcer disease

          -  Acute Gastrointestinal Hemorrhage

          -  Known History of Renal or Hepatic insufficiency

          -  History of allergies to NSAIDs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IKCH</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>July 4, 2020</last_update_submitted>
  <last_update_submitted_qc>July 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tehran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Hadi Mirfazaelian</investigator_full_name>
    <investigator_title>Assistant Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colic</mesh_term>
    <mesh_term>Renal Colic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

